Chordia Therapeutics Inc. (JP:190A) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chordia Therapeutics Inc., a clinical-stage biotech company in Japan, has released a corporate research report through Fisco Corporation. The company is advancing its lead asset, rogocekib, a cancer therapy currently in Phase 1/2 trials in the US, and is working on other promising preclinical cancer treatments. This development could be of interest to investors tracking innovative cancer therapies and biotech advancements.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.